Fischer Medical Ventures Ltd
Incorporated in 1993, Fischer Chemic Ltd does trading of chemicals and machineries[1]
- Market Cap ₹ 5,268 Cr.
- Current Price ₹ 826
- High / Low ₹ 919 / 534
- Stock P/E 2,450
- Book Value ₹ 15.2
- Dividend Yield 0.00 %
- ROCE 1.40 %
- ROE 1.01 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 54.5 times its book value
- Promoter holding has decreased over last quarter: -13.1%
- Earnings include an other income of Rs.3.53 Cr.
- Company has high debtors of 402 days.
- Working capital days have increased from 770 days to 1,215 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.64 | 0.04 | 0.02 | 0.00 | 0.00 | -0.01 | -0.01 | 0.18 | 0.17 | 0.00 | 0.18 | 11.53 | 11.34 | |
2.62 | 0.11 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.20 | 0.19 | 0.19 | 0.16 | 11.72 | 12.12 | |
Operating Profit | -1.98 | -0.07 | -0.06 | -0.12 | -0.14 | -0.20 | -0.18 | -0.02 | -0.02 | -0.19 | 0.02 | -0.19 | -0.78 |
OPM % | -309.38% | -175.00% | -300.00% | -11.11% | -11.76% | 11.11% | -1.65% | -6.88% | |||||
3.24 | 0.07 | 0.09 | 0.09 | 0.07 | 0.20 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 3.53 | |
Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.00 |
Depreciation | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
Profit before tax | 1.06 | 0.00 | 0.03 | -0.03 | -0.07 | 0.00 | 0.01 | -0.04 | -0.04 | -0.20 | 0.00 | 0.54 | 2.72 |
Tax % | -24.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -450.00% | 20.00% | 25.93% | ||||
1.31 | 0.00 | 0.03 | -0.03 | -0.07 | 0.00 | 0.00 | -0.04 | 0.14 | -0.23 | -0.04 | 0.40 | 2.15 | |
EPS in Rs | 3.81 | 0.00 | 0.09 | -0.09 | -0.20 | 0.00 | 0.00 | -2.33 | 8.14 | -13.37 | -2.33 | 0.07 | 0.41 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 76% |
5 Years: | % |
3 Years: | 308% |
TTM: | 2965% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 42% |
TTM: | 2489% |
Stock Price CAGR | |
---|---|
10 Years: | 72% |
5 Years: | 79% |
3 Years: | 153% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.44 | 3.44 | 3.44 | 3.44 | 3.44 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 53.50 | 53.50 |
Reserves | -3.47 | -3.47 | -3.44 | -3.48 | -3.54 | -0.27 | -0.27 | -0.31 | -0.17 | -0.40 | -0.44 | 26.18 | 27.53 |
0.13 | 0.02 | 0.00 | 0.04 | 0.14 | 0.24 | 0.20 | 0.22 | 0.23 | 0.39 | 0.57 | 0.00 | 0.00 | |
0.34 | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 | 0.01 | 0.06 | 0.03 | 0.03 | 0.05 | 12.15 | 0.13 | |
Total Liabilities | 0.44 | 0.02 | 0.03 | 0.02 | 0.04 | 0.14 | 0.11 | 0.14 | 0.26 | 0.19 | 0.35 | 91.83 | 81.16 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 44.62 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.28 | 0.00 |
0.44 | 0.02 | 0.03 | 0.02 | 0.04 | 0.14 | 0.11 | 0.14 | 0.26 | 0.19 | 0.35 | 50.54 | 36.54 | |
Total Assets | 0.44 | 0.02 | 0.03 | 0.02 | 0.04 | 0.14 | 0.11 | 0.14 | 0.26 | 0.19 | 0.35 | 91.83 | 81.16 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.26 | -0.01 | 0.02 | -0.05 | -0.07 | -0.01 | 0.00 | 0.01 | -0.06 | -0.18 | -0.15 | 0.08 | |
2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -37.78 | |
-3.26 | -0.06 | -0.02 | 0.04 | 0.10 | 0.10 | -0.04 | 0.00 | 0.00 | 0.15 | 0.17 | 37.67 | |
Net Cash Flow | 0.00 | -0.07 | 0.00 | -0.01 | 0.03 | 0.09 | -0.03 | 0.01 | -0.06 | -0.03 | 0.02 | -0.03 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 148.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 344.72 | 402.04 | |||
Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 148.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 344.72 | 402.04 | |||
Working Capital Days | 62.73 | -273.75 | -365.00 | 365.00 | 365.00 | -40.56 | 21.47 | 324.44 | 1,215.29 | |||
ROCE % | -466.67% | 0.00% | -350.00% | 0.00% | 8.33% | -22.22% | -12.90% | -97.44% | 8.70% | 1.40% |
Documents
Announcements
-
Board Meeting Intimation for Consideration And Approval Of Audited Financial Results For The Year And Quarter Ended 31.03.2025 And To Recommend Final Dividend If Any And To Transact Other General Matters As Stated In The Agenda
1d - Board meeting on May 28, 2025, to approve FY25 financials and consider dividend declaration.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
16 May - Monitoring report confirms Rs.358.46 Cr preferential issue funds utilized as per objectives, no deviations.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
5 May - Shareholders approved appointment of Ms. Jaya Ankur Singhania as Independent Director on May 3, 2025.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company states it does not qualify as large entity under SEBI debt issuance norms, no borrowings outstanding.
-
Announcement Under Regulation 30
23 Apr - Subsidiary invests USD 12.5M for 15% stake in Singapore biomedical tech firm Nanomedic.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Dec 2024TranscriptNotesPPT
Business Overview:[1]
Company is in the business of processing, manufacturing and trading of Laboratory Grade Chemicals